Table 1.
Animal studies that investigated the therapeutic effects of resveratrol on depression
| Disease | Dose of resveratrol | Model | Findings | Publish year | Refs. |
|---|---|---|---|---|---|
| Chronic unpredictable mild stress-induced depression | 80 mg/kg | In vivo | Inhibited neuro-inflammation, oxidative stress, and apoptosis, increased hippocampal BDNF and β-catenin levels | 2018 | [84] |
| Ovariectomy-induced depression | 20 mg/kg | In vivo | Decreased activation of microglia, NF-kB, and NLRP3 in hippocampus, increased levels of Sirt1 | 2019 | [85] |
| Chronic unpredictable mild stress-induced depression | 80 mg/kg | In vivo | Inhibited oxidative stress, apoptosis and inflammation elevation of serum levels of testosterone and β-catenin | 2019 | [86] |
| Chronic restraint stress- induced depression | 80 mg/kg | In vivo | Increased BDNF levels, and Bcl-2 expression in hippocampus, decreased Bax mRNA expression | 2016 | [7] |
| Subclinical hypothyroidism | 15 mg/kg | In vivo | Decreased TSH, TRH, corticoesterone, and CRH hormones, increased GSK3β phosphorylation, cyclin D1 and c-myc, decreased β-catenin phosphorylation, decreased activity of HPA axis | 2016 | [99] |
| Chronic unpredictable mild stress-induced depression | 15 mg/kg/day | In vivo | Decreased corticosterone and CRH, increased IL-6, CRP, TNF-α, BDNF, βcatenin phosphorylation, decreased the phosphorylation of GSK-3β in hippocampus | 2017 | [100] |
| Chronic unpredictable mild stress-induced depression | 40 or 80 mg/kg/day | In vivo | activated Akt/GSK3β pathway and regulated pro-inflammatory cytokines and apoptosis | 2019 | [101] |
| Ouabain-induced depression | 10 mg/kg | In vitro/in vivo | Decreased oxidative stress and neuro-inflammation | 2018 | [102] |
| Chronic unpredictable mild stress-induced depression | 50 mg/kg | In vivo | Increased hippocampal ATP levels, mitochondrial DNA, the expressions of SIRT1 and PGC1α, decreased Na+-K+-ATPase and pyruvate levels, increased serotonin levels, decreased SERT in the hippocampus | 2020 | [87] |
| LPS-induced depression | 0.3 mg/kg | In vivo | Improved apoptosis and oxidative stress in hippocampus and depressant-like behaviors | 2017 | [88] |
| LPS-induced depression | 20 mg/kg | In vivo | Enhanced neurogenesis, upregulated Sirt1, and inhibited NF-kB activation | 2016 | [89] |
| Chronic unpredictable mild stress-induced depression | 10, 20 and 30 mg/kg | In vivo | Increased dopamine and serotonin in the prefrontal cortex and increased NPY expression in the brain | 2019 | [90] |